Tenderwize
Retour à la recherche

Open-House Biologics Discount Agreements 2026-05 - Pegfilgrastim

Techniker Krankenkasse·Hamburg, Germany·Deadline Apr 29, 2028 · 612 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-05 - Pegfilgrastim

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No estimated contract value or framework maximum value is disclosed. Potential revenue is unknown.

The procedure is not a public procurement under EU directives; legal recourse is via social courts, not procurement tri...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Supply of Pegfilgrastim pharmaceutical products under discount agreements.
  • Nationwide coverage in Germany.
Afficher le résumé complet

Open-House procedure for pharmaceutical discount agreements (Rabattverträge) for the active substance Pegfilgrastim, conducted by Techniker Krankenkasse (lead buyer) together with HEK and hkk. The procedure is open to all eligible pharmaceutical entrepreneurs at any time during the contract period. No estimated value, no award criteria, and no procurement documents were analyzed. The contract duration is 24 months from May 2026 to April 2028.

Risques

No estimated contract value or framework maximum value is disclosed. Potential revenue is unknown.

The procedure is not a public procurement under EU directives; legal recourse is via social courts, not procurement tri...

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur according to § 4 Abs. 18 AMG for the offered medicines.
  • Must have a valid marketing authorization for the medicine(s) in Germany or equivalent.

Administrative

  • Must submit a self-declaration on authorization and company (Anlage 4 zum Vertrag).

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House Biologics Discount Agreements 2026-05 - Pegfilgrastim

Conclusion of pharmaceutical discount agreements according to § 130a Abs. 8 SGB V for Pegfilgrastim via an open-house procedure. All eligible pharmaceutical entrepreneurs can join at any time during the contract period. No exclusivity is granted.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Apr 2026 - Apr 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Apr 29, 2028

Détails de la procédure

Date de publication
18 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
190019-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3